Hyperion Therapeutics is a commercial stage biopharmaceutical company committed to developing and delivering life-changing treatments for orphan diseases. The company’s first commercial product, RAVICTI® (glycerol phenylbutyrate) Oral Liquid, was approved in February 2013 and is currently being marketed in the United States. Hyperion also owns worldwide rights to BUPHENYL® (sodium phenylbutyrate) Tablets and Powder, which it markets in the US. The compound is also marketed internationally through business partners. The company is also developing glycerol phenylbutyrate for the potential treatment of hepatic encephalopathy.
Hyperion Therapeutics completed an Initial Public Offering in July 2012 (NASDAQ:HPTX). In May 2015, Hyperion was acquired by Horizon Pharma (NASDAQ: HZNP).